Paris Research Program

News From Paris Lab

Circulating Tumor Cells Detected in Non-Metastatic Prostate Cancer Setting by the Paris Lab.  Click here to read more.

Click on the link below to read more about our lab’s latest research.

Read More


Lab Members

Pamela L. Paris

Khushboo Singh
Research Staff

Dan Viet
Research Staff

Karla Lindquist
Data Scientist

Terence Friedlander
Assistant Clinical Professor




Click here


Contact information:

UCSF Helen Diller Family Cancer Research Center
1450 Third Street, Office: HD384
Interoffice Mailcode: 3110
San Francisco, CA 94158
415.514.2559  (Phone)

Funding sources:
Current:  NIH R21, DoD, PCF, Cancer League, Hem-Onc Gift, Biomarker Gift, Urology Dept.

The Paris laboratory conducts translational cancer genomics research. Their overarching goal is to identify drug targets with associated prognostic biomarkers. The primary focus has been prostate cancer. Dr. Paris published a landmark paper demonstrating the use of formalin fixed paraffin embedded (FFPE) tissue with array comparative genomic hybridization (aCGH). This research advance makes possible clinically significant studies because stored tissue from patients with prostate cancer with extensive follow-up can now be studied. As a co-leader of a UCSF prostate SPORE program project, Paris helped identify a set of DNA based biomarkers (named GEMCaP for Genomic Evaluators of Metastatic Cancer of the Prostate) that may help identify patients at the time of surgical intervention who are at high-risk of recurrence and metastasis, and therefore may assist Urologists in adjuvant therapy decisions. Their current research is aimed at validating these biomarkers with the goal of bringing a predictive tool into the clinic.  Up and coming work will involve evaluating GEMCaP’s prognostic ability in the Active Surveillance setting.

On the other side of the disease spectrum is castration resistant prostate cancer (CRPC). Ultimately, resistance to androgen deprivation therapy and chemotherapy is the underlying cause of mortality in patients with advanced prostate cancer. A major constraint in studying resistance mechanisms in advanced prostate cancer has been the limited accessibility to metastatic CRPC tissue. In collaboration with the Division of Hematology-Oncology, Paris piloted a project to isolate Circulating Tumor Cells (CTCs) from patients with CRPC. This research moves beyond CTC enumeration studies and genomically profiled CTCs. To the best of our knowledge, this was the first time CTCs had been profiled by high resolution aCGH. Copy number profiles from CTCs could provide potential new drug targets for castration resistant tumors. Current CTC research in the Paris laboratory is focused on CTC platform development and pairing with downstream genomic applications to make CTCs a vital part of personalized medicine.

Contact information:

415-514-2559 (Phone)

University of California San Francisco, Helen Diller Family Cancer Research Building, Department of Urology, 1450 3rd Street, HD384, San Francisco, CA 94158-9001

(UCSF inter-office mail should be sent to Box 3110)

Email: [email protected]